Search Results

You are looking at 101 - 110 of 491 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III, and Tanya Wildes

, depression, distress, osteoporosis, falls, fatigue, and frailty are some of the most common syndromes in elderly cancer patients. 97 Elderly patients with cancer experience a higher prevalence of geriatric syndromes compared with those without cancer. In

Full access

Presenter: Sandy Srinivas

-effect profiles,” Dr. Srinivas said. “The most important side effects of these drugs are fatigue, falls, and fractures.” However, the side-effect profiles of the drugs are somewhat different. The risk of fatigue is higher for apalutamide and enzalutamide (27

Full access

Karen E. Kinahan, Sheetal Kircher, Jessica Altman, Alfred Rademaker, John M. Salsman, Aarati Didwania, Bridget O'Brien, Alpa C. Patel, and Stacy D. Sanford

– 29 Other literature on the use of BPAs highlight “alert fatigue,” which occurs when providers are inundated with too many BPAs and ignore them or work around them. 30 , 31 There was evidence of alert fatigue in our study based on the providers

Full access

Michael H. Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Susan Block, Shirley N. Codada, Shalini Dalal, Maria Dans, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Todd M. Sauer, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Carin Van Zyl, Sharon M. Weinstein, Mary Anne Bergman, and Jillian L. Scavone

care, including pain, nausea, anxiety, depression, dyspnea, fatigue, psychosocial distress, and loss of appetite. 1 Palliative care in oncology began as hospice and end-of-life care. During the past 20 years, increasing attention has been paid to the

Full access

Boyu Hu, Jay L. Patel, Randa Tao, Richard B. Cannon, Marcus Monroe, and Gaurav Goyal

lesion and most of the cervical lymph nodes. After 7 months of therapy, trametinib dose was decreased to 1.5 mg daily due to the patient experiencing grade 2 fatigue, peripheral edema, and acneiform rash. At 1 year of therapy with trametinib, the patient

Full access

Michael Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Anna C. Beck, Susan Block, Shalini Dalal, Maria Dans, Thomas R. Fitch, Jennifer Kapo, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Diane G. Portman, Todd M. Sauer, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman, and Jillian L. Scavone

assessed are pain, dyspnea, anorexia, cachexia, nausea, vomiting, constipation, malignant bowel obstruction, fatigue, weakness, asthenia, insomnia, daytime sedation, and delirium. 4 Palliative interventions for these symptoms are discussed individually in

Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

.2% (3 stringent CRs, 10 VGPRs, 18 PRs). Median response duration was 7.4 months and median time to progression was 3.7 months; the estimated 1-year OS rate was 65%. 22 Adverse events reported included fatigue (39.6%), anemia (33.0%), nausea (29.2%), and

Full access

Renuka Iyer and Kaunteya Reddy

in the placebo group. The most frequent treatment-related adverse events were stomatitis, rash, fatigue, diarrhea, and respiratory infections. Everolimus benefit was due to tumor stabilization in most cases. Promising phase II data prompted another

Full access

Margaret Tempero

quite a while, and travel restrictions remain in effect, which is fine, because all the big professional meetings we enjoy each spring and summer are being held virtually for the second year in a row. I do have mask fatigue, though. I don’t find

Full access

Rebecca M. Shulman, David S. Weinberg, Eric A. Ross, Karen Ruth, Glenn F. Rall, Anthony J. Olszanski, James Helstrom, Michael J. Hall, Julia Judd, David Y.T. Chen, Robert G. Uzzo, Timothy P. Dougherty, Riley Williams, Daniel M. Geynisman, Carolyn Y. Fang, Richard I. Fisher, Marshall Strother, Erica Huelsmann, Sunil Adige, Peter D. Whooley, Kevin Zarrabi, Brinda Gupta, Pritish Iyer, Melissa McShane, Hilario Yankey, Charles T. Lee, Nina Burbure, Lauren E. Laderman, Julie Giurintano, Samuel Reiss, and Eric M. Horwitz

fatigue, joint pain, fever, chills, headache, and nausea. Allergic reactions were rare after both dose 1 (6/1,752) and dose 2 (9/1,261). Postvaccination symptoms for all patients were more likely to be reported by women than by men (77.8% vs 65.5%; P